Matts Wikland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Matts Wikland has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Lars Hamberger
2 shared publicationsM. Wood
Fertility Centre Scandinavia , Box 5418, SE-402 29 Göteborg , Sweden
2 shared publicationsT. Hillensjo
Fertilitetscentrum, Box 5418, SE-402 29 Göteborg, Sweden
2 shared publicationsTorbjörn Hillensjö
2 shared publicationsA. Knutsson
Department of Obstetrics/Gynecology The IVF Unit Sahlgrenska University Hospital Go ¨teborg Sweden
1 shared publicationAlan H. DeCherney
1 shared publication
Latest Publications
- 9 June 2018
- Published by Cambridge University Press (CUP)
In-Vitro Fertilization
The birth of Louise Joy Brown - the world's first baby born following in-vitro fertilization - heralded a medical revolution. Forty years later, many thousands of babies are born each year following IVF. Assisted reproduction is a global industry with a multi-billion dollar turnover. It is a complex mix of science, clinical management, bioethics, and commercial imperatives. Many of the pioneers of IVF are still with us and have a fascinating tale to tell. Here, they relate the story of the development of IVF and related technologies in a way that will prove invaluable to future generations of practitioners seeking to understand the genesis of the specialty. This is not an academic history: rather it takes an informal and anecdotal approach; informing and entertaining for generations of past, present and future medical and scientific specialists of IVF, alongside the millions of parents, who celebrated the successes of IVF treatment worldwide.
- 9 June 2018
- Published by Cambridge University Press (CUP)
In-Vitro Fertilization
The birth of Louise Joy Brown - the world's first baby born following in-vitro fertilization - heralded a medical revolution. Forty years later, many thousands of babies are born each year following IVF. Assisted reproduction is a global industry with a multi-billion dollar turnover. It is a complex mix of science, clinical management, bioethics, and commercial imperatives. Many of the pioneers of IVF are still with us and have a fascinating tale to tell. Here, they relate the story of the development of IVF and related technologies in a way that will prove invaluable to future generations of practitioners seeking to understand the genesis of the specialty. This is not an academic history: rather it takes an informal and anecdotal approach; informing and entertaining for generations of past, present and future medical and scientific specialists of IVF, alongside the millions of parents, who celebrated the successes of IVF treatment worldwide.
- 9 June 2018
- Published by Cambridge University Press (CUP)
- p. 111-119
The Development of In-Vitro Fertilization in Scandinavia
- 9 June 2018
- Published by Cambridge University Press (CUP)
- p. 111-119
The Development of In-Vitro Fertilization in Scandinavia
- Open Access
- 14 October 2014
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 29 (12) , 2695-2703
Patient-centred quality of care in an IVF programme evaluated by men and women
Do men and women value the same aspects of quality of care during IVF treatment when measuring rates of importance by the validated instrument, quality from the patient's perspective of in vitro fertilization (QPP-IVF)? Women valued most aspects of care as significantly more important than their partner although men and women evaluated the importance of the different care factors in a similar pattern. A few validated tools measuring patient-centred quality of care during IVF have been developed. Few studies of gender differences concerning experiences of patient-centred quality of care have been reported in the literature to date. A two-centre study was conducted between September 2011 and May 2012. Heterosexual couples (n = 497) undergoing IVF were invited to complete a questionnaire before receiving the result of the pregnancy test. In all, 363 women and 292 men evaluated quality of care by answering the QPP-IVF questionnaire. The measurements consisted of two kinds of evaluations: the rating of the importance of various aspects of treatment (subjective importance) and the rating of perceived quality of care (perceived reality). Comparisons between men and women on importance ratings and perceived reality ratings were performed both on factor (subscale) and single item levels by intra-couple analyses and corrected for age. A stepwise multiple logistic regression analysis was performed in order to select baseline variables independently predicting evaluation at factor level. The response rate was 67.5%, with 363 women (74.2%) and 292 men (60.6%) completing the study. Both the woman and man responded in 251 couples. Women rated the different care aspects as significantly more important than their partner in all factors except the factor, ‘Responsibility/continuity’. Both genders gave the factors, ‘Medical care’ and ‘Information after treatment’, the highest scores. At item level women rated the majority of items as significantly more important than men. Perceived reality for the majority of factors and items was similarly rated by men and women in the couples. For women, receiving embryo transfer, short duration of infertility, IVF as a method and number of previous cycles were independently correlated to the highest score of importance of certain factors. The lower response rate of men compared with women (60.6 versus 74.2%, respectively) might have influenced the results through selection bias. Only patients who had adequate fluency in the Swedish language participated. This study is an important contribution in comparing the needs of men and women undergoing IVF treatments. The QPP-IVF instrument is a suitable instrument for revealing important care aspects identified by both men and women and a useful tool for stimulating patient-centred quality improvements within and between clinics. The study was supported by the LUA/ALF agreement at Sahlgrenska University Hospital, Gothenburg, Sweden, and by Hjalmar Svensson's Research Foundation. None of the authors declared any conflict of interests.
- 14 October 2014
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 29 (12) , 2695-2703
Open AccessPatient-centred quality of care in an IVF programme evaluated by men and women
Do men and women value the same aspects of quality of care during IVF treatment when measuring rates of importance by the validated instrument, quality from the patient's perspective of in vitro fertilization (QPP-IVF)? Women valued most aspects of care as significantly more important than their partner although men and women evaluated the importance of the different care factors in a similar pattern. A few validated tools measuring patient-centred quality of care during IVF have been developed. Few studies of gender differences concerning experiences of patient-centred quality of care have been reported in the literature to date. A two-centre study was conducted between September 2011 and May 2012. Heterosexual couples (n = 497) undergoing IVF were invited to complete a questionnaire before receiving the result of the pregnancy test. In all, 363 women and 292 men evaluated quality of care by answering the QPP-IVF questionnaire. The measurements consisted of two kinds of evaluations: the rating of the importance of various aspects of treatment (subjective importance) and the rating of perceived quality of care (perceived reality). Comparisons between men and women on importance ratings and perceived reality ratings were performed both on factor (subscale) and single item levels by intra-couple analyses and corrected for age. A stepwise multiple logistic regression analysis was performed in order to select baseline variables independently predicting evaluation at factor level. The response rate was 67.5%, with 363 women (74.2%) and 292 men (60.6%) completing the study. Both the woman and man responded in 251 couples. Women rated the different care aspects as significantly more important than their partner in all factors except the factor, ‘Responsibility/continuity’. Both genders gave the factors, ‘Medical care’ and ‘Information after treatment’, the highest scores. At item level women rated the majority of items as significantly more important than men. Perceived reality for the majority of factors and items was similarly rated by men and women in the couples. For women, receiving embryo transfer, short duration of infertility, IVF as a method and number of previous cycles were independently correlated to the highest score of importance of certain factors. The lower response rate of men compared with women (60.6 versus 74.2%, respectively) might have influenced the results through selection bias. Only patients who had adequate fluency in the Swedish language participated. This study is an important contribution in comparing the needs of men and women undergoing IVF treatments. The QPP-IVF instrument is a suitable instrument for revealing important care aspects identified by both men and women and a useful tool for stimulating patient-centred quality improvements within and between clinics. The study was supported by the LUA/ALF agreement at Sahlgrenska University Hospital, Gothenburg, Sweden, and by Hjalmar Svensson's Research Foundation. None of the authors declared any conflict of interests.
- Open Access
- 5 April 2011
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 26 (6) , 1377-1383
A randomized controlled study comparing pain experience between a newly designed needle with a thin tip and a standard needle for oocyte aspiration
Ultrasound-guided transvaginal oocyte retrieval is often performed under local anaesthesia on an outpatient basis. The objective of this study was to compare the overall pain experience of a newly designed reduced needle (RN) compared with a thicker standard needle (SN). A prospective, randomized, multi-centre study was performed at four different clinics from June to December 2009. The oocyte aspiration was performed under local anaesthesia, either with a needle with a reduced diameter (0.9 mm) for the last 50 mm from the tip (RN) or with a SN (1.4 mm). A total of 257 patients were randomized (RN: n = 129; SN: n = 128). The primary endpoint was the overall pain experience self-assessed and registered by the patient on a visual analogue scale (VAS 0 mm = no pain to 100 mm = unbearable pain) immediately after the oocyte retrieval. Secondary end-points such as vaginal bleeding and several embryological parameters were also registered. The overall pain during the oocyte retrieval procedure was significantly lower in the RN group than in the SN group (mean 21.0 mm, SD 17.5 mm and median 19.0 mm versus mean 26.0 mm, SD 19.9 mm and median 24.0 mm; P = 0.040, difference between groups mean−5.0 mm, 95% CI: 9.7 to−0.4). This was also true when adjusting for baseline characteristics such as number of follicles, number of previous oocyte pick-up, body mass index and age, by a multiple linear regression analysis. Significantly more patients (40 of 126) had less than expected vaginal bleeding in the RN group when compared with the SN group (24 of 124; 32 versus 19%; P = 0.03 and 95% CI 1.7–23.0%). No differences were found between the two needles with regard to additional i.v. analgesia, aspiration time, oocyte recovery, fertilization, cleavage rate, number of good quality embryos, number of embryos for freezing and pregnancy rate. Oocyte aspiration performed with the newly designed thinner-tipped needle resulted in significantly less overall pain and less vaginal bleeding, without prolonging the retrieval procedure or influence the oocyte recovery rate, when compared with a SN. Clinicaltrials.gov: NCT00924885
- 5 April 2011
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 26 (6) , 1377-1383
Open AccessA randomized controlled study comparing pain experience between a newly designed needle with a thin tip and a standard needle for oocyte aspiration
Ultrasound-guided transvaginal oocyte retrieval is often performed under local anaesthesia on an outpatient basis. The objective of this study was to compare the overall pain experience of a newly designed reduced needle (RN) compared with a thicker standard needle (SN). A prospective, randomized, multi-centre study was performed at four different clinics from June to December 2009. The oocyte aspiration was performed under local anaesthesia, either with a needle with a reduced diameter (0.9 mm) for the last 50 mm from the tip (RN) or with a SN (1.4 mm). A total of 257 patients were randomized (RN: n = 129; SN: n = 128). The primary endpoint was the overall pain experience self-assessed and registered by the patient on a visual analogue scale (VAS 0 mm = no pain to 100 mm = unbearable pain) immediately after the oocyte retrieval. Secondary end-points such as vaginal bleeding and several embryological parameters were also registered. The overall pain during the oocyte retrieval procedure was significantly lower in the RN group than in the SN group (mean 21.0 mm, SD 17.5 mm and median 19.0 mm versus mean 26.0 mm, SD 19.9 mm and median 24.0 mm; P = 0.040, difference between groups mean−5.0 mm, 95% CI: 9.7 to−0.4). This was also true when adjusting for baseline characteristics such as number of follicles, number of previous oocyte pick-up, body mass index and age, by a multiple linear regression analysis. Significantly more patients (40 of 126) had less than expected vaginal bleeding in the RN group when compared with the SN group (24 of 124; 32 versus 19%; P = 0.03 and 95% CI 1.7–23.0%). No differences were found between the two needles with regard to additional i.v. analgesia, aspiration time, oocyte recovery, fertilization, cleavage rate, number of good quality embryos, number of embryos for freezing and pregnancy rate. Oocyte aspiration performed with the newly designed thinner-tipped needle resulted in significantly less overall pain and less vaginal bleeding, without prolonging the retrieval procedure or influence the oocyte recovery rate, when compared with a SN. Clinicaltrials.gov: NCT00924885
- Open Access
- 15 May 2010
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 25 (7) , 1699-1707
Obstetric outcomes after transfer of vitrified blastocysts
It has been claimed that the risks to the child resulting from vitrification as compared with the slow-freezing technique, may be higher owing to the high concentrations of potentially toxic cryoprotectants. We therefore retrospectively compared the obstetric and neonatal outcomes in a cohort of children born after transfer of vitrified blastocysts, fresh blastocysts and slow-frozen early cleavage stage embryos. All children born after transfer of vitrified blastocysts (n = 106), fresh blastocysts (n = 207) and slow-frozen early cleavage stage embryos (n = 206) during the period January 2006 to May 2008 at Fertility Center Scandinavia were included. Data on obstetric and neonatal outcomes were obtained from medical records from the antenatal and delivery clinics. For singletons, there were no significant differences between the groups in gestational age, mortality or birth defects. After adjustment for parity and BMI, birthweight was significantly higher in singletons born after transfer of vitrified blastocysts as compared with after transfer of fresh blastocysts (median 3560 versus 3510 g, P = 0.0311). More singletons born after transfer of fresh blastocysts were small for gestational age compared with singletons born after transfer of vitrified blastocysts (12.1 versus 3.0%, P = 0.0085). A higher rate of major post-partum haemorrhage was observed in the vitrified blastocyst group as compared with the other two groups (25.0 versus 6.0 and 7.5%). No adverse neonatal outcomes were observed in children born after transfer of vitrified, as compared with fresh blastocysts or after transfer of slow-frozen early cleavage stage embryos.
- 15 May 2010
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 25 (7) , 1699-1707
Open AccessObstetric outcomes after transfer of vitrified blastocysts
It has been claimed that the risks to the child resulting from vitrification as compared with the slow-freezing technique, may be higher owing to the high concentrations of potentially toxic cryoprotectants. We therefore retrospectively compared the obstetric and neonatal outcomes in a cohort of children born after transfer of vitrified blastocysts, fresh blastocysts and slow-frozen early cleavage stage embryos. All children born after transfer of vitrified blastocysts (n = 106), fresh blastocysts (n = 207) and slow-frozen early cleavage stage embryos (n = 206) during the period January 2006 to May 2008 at Fertility Center Scandinavia were included. Data on obstetric and neonatal outcomes were obtained from medical records from the antenatal and delivery clinics. For singletons, there were no significant differences between the groups in gestational age, mortality or birth defects. After adjustment for parity and BMI, birthweight was significantly higher in singletons born after transfer of vitrified blastocysts as compared with after transfer of fresh blastocysts (median 3560 versus 3510 g, P = 0.0311). More singletons born after transfer of fresh blastocysts were small for gestational age compared with singletons born after transfer of vitrified blastocysts (12.1 versus 3.0%, P = 0.0085). A higher rate of major post-partum haemorrhage was observed in the vitrified blastocyst group as compared with the other two groups (25.0 versus 6.0 and 7.5%). No adverse neonatal outcomes were observed in children born after transfer of vitrified, as compared with fresh blastocysts or after transfer of slow-frozen early cleavage stage embryos.
- 31 December 2006
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 12 (6) , 663-668
Improving the consistency of ovarian stimulation: follitropin alfa filled-by-mass
- 31 December 2006
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 12 (6) , 663-668
Improving the consistency of ovarian stimulation: follitropin alfa filled-by-mass
- Open Access
- 1 August 2001
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 16 (8) , 1676-1681
A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI
BACKGROUND: A prospective randomized study was carried out in two centres to compare the number of oocytes retrieved after two different starting doses of recombinant human FSH (rhFSH) (Gonal-F®) in women undergoing ovarian stimulation for IVF/intracytoplasmic sperm injection (ICSI) cycles using the multiple dose regimen of the gonadotrophin-releasing hormone (GnRH) antagonist cetrorelix (Cetrotide®) to prevent induction of the premature LH surge. METHODS: Sixty women were randomized to receive rhFSH 150 IU (`low'), and 60 women to receive rhFSH 225 IU (`high') as the starting dose for the first 5 days of stimulation. From stimulation day 6 and onwards, including the day of human chorionic gonadotrophin (HCG) administration, the women received 0.25 mg of cetrorelix as a daily dose. The primary endpoint was the number of oocytes retrieved. RESULTS: The mean number (± SD) of oocytes was 9.1 ± 4.4 and 11.0 ± 4.6 in the `low' and `high' groups respectively (P = 0.024). The mean number of 75 IU ampoules of rhFSH was significantly lower in the `low' group (23.0 ± 6.3 versus 30.5 ± 5.6, P < 0.0001). The ongoing pregnancy rate per started cycle and per embryo transfer were 25.9 and 28.8% versus 25.4 and 26.8% respectively in the `low' and `high' rhFSH groups (P = NS). CONCLUSIONS: When using a starting dose of 225 IU rhFSH combined with the multiple dose of 0.25 mg cetrorelix from stimulation day 6, significantly more oocytes were obtained than with a starting dose of 150 IU rhFSH.
- 1 August 2001
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 16 (8) , 1676-1681
Open AccessA prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI
BACKGROUND: A prospective randomized study was carried out in two centres to compare the number of oocytes retrieved after two different starting doses of recombinant human FSH (rhFSH) (Gonal-F®) in women undergoing ovarian stimulation for IVF/intracytoplasmic sperm injection (ICSI) cycles using the multiple dose regimen of the gonadotrophin-releasing hormone (GnRH) antagonist cetrorelix (Cetrotide®) to prevent induction of the premature LH surge. METHODS: Sixty women were randomized to receive rhFSH 150 IU (`low'), and 60 women to receive rhFSH 225 IU (`high') as the starting dose for the first 5 days of stimulation. From stimulation day 6 and onwards, including the day of human chorionic gonadotrophin (HCG) administration, the women received 0.25 mg of cetrorelix as a daily dose. The primary endpoint was the number of oocytes retrieved. RESULTS: The mean number (± SD) of oocytes was 9.1 ± 4.4 and 11.0 ± 4.6 in the `low' and `high' groups respectively (P = 0.024). The mean number of 75 IU ampoules of rhFSH was significantly lower in the `low' group (23.0 ± 6.3 versus 30.5 ± 5.6, P < 0.0001). The ongoing pregnancy rate per started cycle and per embryo transfer were 25.9 and 28.8% versus 25.4 and 26.8% respectively in the `low' and `high' rhFSH groups (P = NS). CONCLUSIONS: When using a starting dose of 225 IU rhFSH combined with the multiple dose of 0.25 mg cetrorelix from stimulation day 6, significantly more oocytes were obtained than with a starting dose of 150 IU rhFSH.
- 1 August 2000
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 166 (1) , 3-7
The application of quality systems in ART programs
- 1 August 2000
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 166 (1) , 3-7
The application of quality systems in ART programs